POSTERS PRESENTED ONSITE IN BOSTON

These posters will be available onsite in Boston in the Poster Hall and on the digital platform in PDF format

Theme: Animal model and clinical trials

P1 Treatment of Alzheimer’s disease by a proteosome-based adjuvant (Protollin) that modulates both peripheral monocytes and disease-associated microglia
Panayota Kolypetri, Brigham Women’s Hospital – Boston, MA (USA)

P5 Measuring neuropsychiatric symptoms in early dementia patients using speech analysis
Alexandra König 1,2, Elisa Mallick 3, Johannes Tröger 1, Nicklas Linz 3, Radia Zegahri 2, Valeria Manera 2, Philippe Robert 2
1 Institut National de Recherche en Informatique et en Automatique (INRIA). Stars Team. Sophia Antipolis. Valbonne. France - Valbonne (France), 2 Cobtek (Cognition-Behaviour-Technology) Lab, FRIS-University Côte d’azur, Nice, France - Nice (France), 3 Ki:elements, Saarbrücken, Germany - Saarbrücken (Germany)

Theme: Behavioral disorders and clinical trials

P2 Mapping Items of the Cohen-Mansfield Agitation Inventory onto International Psychogeriatric Association’s agitation definition: data from the brexipiprazole phase 3 program for the treatment of agitation in Alzheimer’s dementia
Ross A. Baker 1, Eva Kohegyi 1, Ismail Zahinoor 2
1 Otsuka – Princeton, NJ (USA), 2 University of Calgary - Calgary (Canada)

P3 Veterans in AD Prevention Clinical Trials: An evaluation of the association of TBI on memory and global cognition
Carol Van Hulle 1, Madison Rundell 1, Karen Lazar 1, Elena Beckman 1, Noele Brandon 1, Carey Gleason 1, Sterling Johnson 1, Sanjay Asthana 1, Cynthia Carlsson 1
University of Wisconsin-Madison – Madison, WI (USA)

P4 Low dose lithium treatment of behavioral complications in Alzheimer’s disease: Lit-AD randomized clinical trial
Davangere Devanand 1, Elizabeth Crocco 1, Brent Forester 1, Mustafa Husain 1, Seonjoo Lee 1
Columbia University Irving Medical Center - New York (USA)

P7 iADRS: demonstration of clinical meaningfulness by association of health-related quality of life outcome assessments
Julie Chandler 1, Mark Belger 1, Alette Wessels 1, Joe Johnston 1, Dorene Rentz 2,3, James Murray 1, John Sims 1
P8 Repeated administration of autologous adipose tissue-derived stem cells improved cognitive function in Alzheimer’s disease
Kazuo Shigematsu 1,2, Kazunari Ishii 3, Naoyuki Komori 2, Kenichi Tahara 4, Hisakazu Yamagishi 5
1Minami Kyoto Hospital - Joyo (Japan), 2Nagitsuji Hospital - Kyoto (Japan), 3Department Of Radiology, Kindai University Faculty Of Medicine - Osaka, Japan, 4Takara Bio Inc - Kusatsu (Japan), 5Kyoto Prefectural University Of Medicine - Kyoto (Japan)

P9 The Influence of Level of Education on Instrumental Activities of Daily Living in Patients with Alzheimer’s Disease
Carina Wattmo, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)

P10 Low-dose Whole Brain Radiation Therapy for Early Alzheimer’s Dementia: Early Results from a Phase IIa Trial
Leland Rogers 1, Sarah Lageman 2, John Karis 3, Minesh Mehta 4, James Fontanesi 5
1Gammawest Cancer Services - Salt Lake City, Ut (USA), 2Virginia Commonwealth University - Richmond, Va (USA), 3Barrow Neurological Institute - Phoenix, Az (USA), 4Miami Cancer Institute - Miami, Fl (USA), 5William Beaumont Hospital - Auburn Hills, Mi (USA)

P11 AMBAR Treatment Effect Size Compared to Monoclonal Antibody Study Effect Sizes
Samuel Dickson 1, Suzanne Hendrix 1, Jessie Nicodemus Johnson 1, Miquel Barcelo 2, Merce Boada 3,4, Oscar Lopez 5, Laura Nunez 2, Carlota Grifols 2, Antonio Paez 2
1Pentara Corporation - Millcreek (USA), 2Grifols - Barcelona (Spain), 3Universitat Internacionnal De Catalunya - Barcelona (Spain), 4Instituto de Salud Carlos III - Madrid (Spain), 5Universitat Internacionnal De Catalunya - Pittsburgh (USA)

Theme: Clinical trials: imaging

P12 An automated MRI face-removal pipeline to anonymize patient scans for clinical trials
Lukasz Kidzinski 1, Thomas Cajgfinger 2, Kevin Thomas 1, Luc Bracoud 2, Po-Han Chen 3, Shao-Yu Lin 3, Joonmi Oh 1, Chun-Chiang Shen 3, Chris Conklin 4, Joël Schaerer 2, David Scott 1, Joyce Suhy 1
1Bioclinica - San Mateo (USA), 2Bioclinica - Lyon (France), 3Bioclinica - Taiwan (Taiwan, Republic of China), 4Bioclinica - Princeton (USA)

P13 Free water imaging as a tool for understanding Alzheimer’s Disease
Richard Parker 1, Richard Joules 1, Robin Wolz 1
Ixico Plc - London (United Kingdom)

P14 Impact of Age and APOE4 carrier status in subjects at-risk for AD on microhemorrhages, white matter lesions and brain volume: Preliminary analyses
Luc Bracoud 1, Marie-Emmanuelle Rivière 2, David Scott 3, Chris Conklin 4, Angelika Caputo 2, Joyce Suhy 3, Ana Graf 2
1Bioclinica - Lyon (France), 2Novartis Pharma Ag - Basel (Switzerland), 3Bioclinica - San Mateo (USA), 4Bioclinica - Princeton (USA)
P15 Towards computer-assisted detection of ARIA-E occurrence
Thomas Cajgfinger 1, Luc Bracoud 1, Derk Purcell 2, Joel Schaerer 1, Marco Lyons 3, Szofia Bullain 3, Jakub Wojtowicz 4, Chris Conklin 5, David Scott 6, Joyce Suhy 6, Gregory Klein 4
1Bioclinica - Lyon (France), 2California Pacific Medical Center - San Francisco (USA), 3Roche/Genentech Product Development, Neuroscience - Basel (Switzerland), 4Roche Pharma Research and Early Development - Basel (Switzerland), 5Bioclinica - Princeton (USA), 6Bioclinica - San Mateo (USA)

P16 Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 2 proof-of-concept clinical trial using hippocampal volume as a surrogate endpoint
Gerson Hernandez 1, Lon Schneider 2, Dawn Matthews 3, Kathleen Rodgers 1, Claudia Lopez 1, Yvette Wang 1, Adam Raikes 1, Gary Cutter 4, Roberta Brinton 1
1Center For Innovation In Brain Science, University Of Arizona - Tucson (USA), 2Keck School Of Medicine Of USC - Los Angeles (USA), 3Adm Diagnostics - Chicago (USA), 4Uab School Of Public Health - Birmingham (USA)

P17 Safety, Tolerability and Cerebral Blood Flow After Single Doses of the β2-agonist, Clenbuterol, in Patients with Mild Cognitive Impairment or Parkinson’s Disease
Thomas Lodeweyckx 1, Jan De Hoon 1, Koen Van Laere 2, Michel Koole 1, Wim Vandenberghhe 3, Courtney Bishop 4, Eugenii Rabiner 4, Renee Martin 5, Anthony Ford 5, Gabriel Vargas 5
1Department Of Pharmaceutical And Pharmacological Sciences, University Hospital Leuven And Nuclear Medicine And Molecular Imaging - Durham (USA), 2Department Of Neurology, University Hospital Leuven - Leuven (Belgium), 3Division Of Nuclear Medicine, University Hospital Leuven And Nuclear Medicine And Molecular Imaging - Durham (USA), 4Invicro, A Konica Minolta Company - London (United Kingdom), 5Curasen Therapeutics, Inc - San Carlos, California (USA)

P18 Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology
Yan Sun 1, Jintai Yu 2, Lan Tan 2
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. - Qingdao (China), 2Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Shanghai (China)

P19 Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
Lyduine Collij 1, Sophie Mastenbroek 1, Gemma Salvadó 2, Alle Meie Wink 1, Pieter Jelle Visser 1, Frederik Barkhof 2, Bart Berckel Van 1, Isadora Lopes Alves 1
1Amsterdam Umc - Amsterdam (Netherlands), 2Barcelona Beta Brain Research Center - Barcelona (Spain)
Theme: Clinical trials: biomarkers including plasma

**P20 Microglia biomarkers in Alzheimer’s disease**
Peng-Fei Zhang, Qingdao University - Qingdao (China)

**P21 Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia**
Yan Sun 1, Jintai Yu 2, Lan Tan 3
1Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China, 2Qingdao (China), 3Department Of Neurology And Institute Of Neurology, huashan hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)

**P22 Alzheimer’s disease Patients have Impaired CSF Egress due to Atrophy of the Cribriform Plate**
Douglas Ethell 1, 2, Ricardo Zaragoza 1, Javed Siddiqi 3, Daniel Miuli 4
1Leucadia Therapeutics Inc - Riverside (USA), 2La Jolla Immunology Institute - San Diego (USA), 3Desert Regional Med Ctr - Palm Springs (USA), 4Arrowhead Regional Med Ctr - Colton (USA)

**P23 Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease**
Shi-Dong Chen 1, Qiang Dong 1, Jin-Tai Yu 1
Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University - Shanghai (China)

**P24 Can EEG biomarkers differentiate Alzheimer’s disease dementia vs. non-AD dementia?**
Pieter Van Mierlo, Ghent University - Ghent (Belgium), Epilog Nv - Ghent (Belgium)

**P25 Cerebrospinal fluid platelet-derived growth factor receptor-β measured in BioFINDER 2: a marker of microvascular damage?**
Claudia Cicognola 1, 2, Shorena Janelidze 1, Danielle Van Westen 3, 4, Khazar Ahmadi 1, Oskar Hansson 1, 2
1Clinical Memory Research Unit, Lund University (Sweden), 2Memory Clinic, Skåne University Hospital (Sweden), 3Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University (Sweden), 4Image and Function, Skåne University Hospital, Malmö (Sweden)

**P26 Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF and PET**
Guo Yu, Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China - Shanghai (China)
P27 Placebo-effect size in symptomatic Alzheimer’s Disease Clinical Trials
Nadine Mader 1, Peter Schueler 2
1Univ Duisburg Essen - Bad Vilbel (Germany), 2Icon - Langen (Germany)

Isabella Santangelo 1, Morgan Green 1, Regan Patrick 1, David Harper 1, Tao Song 1, Chenyanwen Zhu 1, Boyu Ren 1, Brent Forester 1, Fei Du 1
Mclean Hospital - Belmont (USA)

P29 Effects of Exclusion Criteria on Disease Modifying Clinical Trials for Alzheimer’s Disease
Aaron Ritter 1, Joel Adu-Brimpong 1, Marwan Sabbagh 1, Jiong Shi 1, Justin Miller 1, Jessica Caldwell 1
Cleveland Clinic - Las Vegas (USA)

P30 Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer’s Dementia.
Kaitlin Mcmanus 1, Rosemary Smith 1, Regan Patrick 1, David Harper 1, Staci Gruber 1, Brent Forester 1
Mclean Hospital - Boston (USA)

P31 ECT-AD Trial: Challenges to Startup & Recruitment
Maria Lapid 1, Brent Forester 1, George Petrides 9, Adriana Hermida 4, Louis Nykamp 5, Martina Mueller 6, Regan Patrick 2
1Mayo Clinic - Rochester, Mn (USA), 2Mclean Hospital - Belmont, Ma (USA), 3Northwell Health/zucker Hillside Hospital - Glen Oaks, Ny (USA), 4Emory University Healthcare - Atlanta, Ga (USA), 5Pine Rest Christian Mental Health Services - Grand Rapids, Mi (USA), 6Medical University Of South Carolina - Charleston, Sc (USA)

P32 The Impact of MMSE Administration Errors on MMSE Change One Year After Randomization: A Preliminary Analysis of Pooled Data
David Miller 1, Xingmei Wang 1, Alan Kott 2
1Signant Health - Blue Bell, PA (USA), 2Signant Health - Prague (Czech Republic)

P33 The ANeED Study: Ambroxol in New and Early Dementia with Lewy Bodies
Arvid Rongve, Haugesund (Norway)

P34 Age affects clinical outcome in Alzheimer’s disease trials
Steven Targum 1, Lisa Fosdick 2, Kristin Drake 1, Paul Rosenberg 4, Anna Burke 5, David Wolk 6, Kelly Foote 7, Wael Asaad 8, Marwan Sabbagh 9, Gwenn Smith 4, Andres Lozano 10, Constantine Lyketsos 4
1Functional Neuromodulation Ltd - Boston (USA), 2Functional Neuromodulation Ltd - Phoenix (USA), 3Functional Neuromodulation Ltd - Dallas (USA), 4Johns Hopkins University School Of Medicine - Baltimore (USA), 5Department Of Neurology, Barrow Neurological Institute - Phoenix (USA), 6University Of Pennsylvania - Philadelphia (USA), 7University Of Florida, Fixel Institute For Neurological Diseases - Gainesville (USA), 8Alpert Medical School Of Brown University - Providence (USA), 9Cleveland Clinic Lou Ruvo Center For Brain Health - Las Vegas (USA), 10University Of Toronto - Toronto (Canada)
Effects of inclusion/exclusion criteria on ethnocultural and socioeconomic composition of participants in an Alzheimer’s disease clinical trial: Analysis of Health and Retirement Study (HRS) data
Miriam T. Ashford 1, Mohammed U. Kabeto 2, Caroline R. Wixom 3, 4, 5, Rachel L. Nosheny 6, Michael W. Weiner 7, David R. Weir 8, Kenneth M. Langa 8, 9, 10
1Northern California Institute For Research And Education (ncire), Department Of Veterans Affairs Medical Center - San Francisco (USA), 2Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 3General Medicine, Department Of Internal Medicine, University Of Michigan - Ann Arbor (USA), 4Department of Medicine, University of California San Francisco - San Francisco (USA), 5Department of Neurology, University of California San Francisco - San Francisco (USA), 6Department Of Psychiatry, University Of California San Francisco - San Francisco (USA), 7Department Of Radiology And Biomedical Imaging, University Of California San Francisco - San Francisco (USA), 8Institute For Social Research, University Of Michigan - Ann Arbor (USA), 9Department of Medicine, University of Michigan - Ann Arbor (USA), 10Institute for Healthcare Policy and Innovation, University of Michigan - Ann Arbor (USA)

A machine learning tool to enrich early Alzheimer’s disease clinical trial cohorts
Angela Tam 1, César Laurent 1, Christian Dansereau 1
Perceiv Research Inc - Montreal (Canada)

Enhancing the Enrollment of Underrepresented Minority Populations in Clinical Trials Through the Global Alzheimer’s Platform Foundation’s® (GAP’s) Diversity and Inclusion Program
Tamiko Rodgers 1, Leigh Zisko 1, John Dwyer 1, Judith Jeter 1, Cyndy Cordell 1
Global Alzheimer’s Platform Foundation – Washington, DC (USA)

Comprehensive evaluations of some mixed models for clinical trial analysis in Alzheimer disease
Guoqiao Wang, Washington University In St Louis - St Louis, MI (USA)

Predicting Amyloid Positivity Using Machine Learning-Based Risk Scores
Kellen Petersen 1, Ali Ezzati 1, Richard Lipton 1, Ellen Grober 1
Albert Einstein College of Medicine – Bronx, NY (USA)

Determining the Probability of Success in a Clinical Development Program for a Disease Modifying AD Treatment
Suzanne Hendrix 1, Newman Knowlton 1, Jessie Nicodemus Johnson 1, Sean Hennessey 1, Samuel Dickson 1
Pentara Corporation - Salt Lake City (USA)

Theme: Clinical trials: results

Single and multiple ascending dose studies in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme
Paul Goldsmith 1, Stephen Lowe 1, Krista Phipps 1, Kevin Donnelly 1, Kevin Biglan 1, Michele Mancini 1, Hugh Nuthall 1, Dustin J. Mergott 1, William Kielbasa 1
Eli Lilly And Company, Lilly Corporate Center - Indianapolis (USA)

CPAD: Accelerating Alzheimer’s disease drug development through pre-competitive data sharing and generation of data-driven quantitative drug development tools
P43 Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers

William Kielbasa 1, Sergey Shcherbinin 1, Paul Goldsmith 1, Krista M. Phipps 1, Kevin Biglan 1, Michele Mancini 1, David Russell 1, Cristian Constantinescu 1, Roger N. Gunn 3, Hugh N. Nuthall 1, Dustin J. Mergott 1, Stephen Lowe 1, Emily C. Collins 1

1Alector Inc., Lilly Corporate Center, Indianapolis (USA), 2Invicro, A Konica Minolta Company New Haven - Connecticut (USA), 3Invicro, A Konica Minolta Company, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road - London (United Kingdom)

P44 ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer's disease: Results of a phase 2, randomized, double-blind, placebo-controlled study.

Olivier Sol 1, Saskia Delpretti 1, Marija Vukicevic 1, Merja Hallikainen 2, Roy Jones 3, Anne Börjesson-Hanson 4, Aliya Asher 4, Alex Thompson 6, Christopher Kipps 7, Emer McSweeney 8, Tanja Touilloux 1, Julian Gray 1, Nicolas Fournier 1, Valérie Hliva 1, Antonio Melo Dos Santos 1, Mika Scheinin 9, 10, Marie Kosko-Vilbois 1, Johannes Streffer 1, 11, Andrea Pfeifer 1, Juha Rinne 9, 10

1Ac Immune Sa - Lausanne (Switzerland), 2University Of Eastern Finland - Kuopio (Finland), 3University Of Bath - Bath (United Kingdom), 4Karolinska University Hospital - Stockholm (Sweden), 5Mac Clinical Research - Manchester (United Kingdom), 6Mac Clinical Research - Canock (United Kingdom), 7Southampton General Hospital - Southampton (United Kingdom), 8Cognition Health Ltd. - Guildford (United Kingdom), 9University Of Turku - Turku (Finland), 10CRST Oy - Turku (Finland), 11Department of Biomedical Sciences, University of Antwerp - Antwerp (Belgium)

P45 A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer's disease

Mike Ward 1, Felix Yeh 1, Hua Long 1, Tina Schwabe 1, Herve Rhinn 1, Ilaria Tassi 1, Daniel Maslyar 1, Madeline Spencer 1, Candace Hagey 1, Glenn Morrison 1, Robert Paul 1

Alector, Inc. - South San Francisco (USA)

P46 A First-in-human Study of the anti-Sortilin antibody AL101

Mike Ward 1, Daniel Maslyar 1, Felix Yeh 1, Hua Long 1, Michael Kurnellas 1, Emmanuel Ang 1, Amber Silva 1, Robert Paul 1

Alector Inc. - South San Francisco (USA)

P47 Evaluation of Pharmaco EEG Outcomes in Subjects Administered Alpha-1062 a Galantamine Prodrug in a Multiple Ascending Dose Study.

Denis Kay 3, Ellen T’hart 2, Charlotte Bakker 2, Klaus Linkenkaer-Hansen 3, Frederick Sancilio 4, Bryce Ortiz 5, Simon-Shlomo Poil 6, Geert-Jan Groeneveld 7

1Alpha Cognition (Canada) Inc. - Charlottetown (Canada), 2Center For Human Drug Research - Leiden (Netherlands), 3Aspect Neuroprofiles Bv & Vu Amsterdam - Amsterdam (Netherlands), 4Alpha Cognition (USA) Inc And Florida Atlantic University - Dallas (USA), 5Alpha Cognition (usa) Inc - Dallas (USA), 6Aspect Neuroprofiles Bv - Eindhoven (Netherlands), 7Center For Human Drug Research And Leiden University Medical Center - Leiden (Netherlands)
Theme: Cognitive assessment and clinical trials

P48 Cultural Influence on CDR Scores: Comparison across Seven Geo-Cultural Groups
Sayaka Machizawa 1, Todd Feaster 1, Jessica Stenclick 1, Zinan Chen 1, Danielle Digregorio 1
Signant Health - Blue Bell (USA)

P49 Geo-Cultural Influences on MMSE Total Score in Alzheimer's Disease Trials
Jessica Stenclick 1, Sayaka Machizawa 1, Zinan Chen 1, Todd Feaster 1
Signant Health - Blue Bell (USA)

P50 Different methods of identifying rapid cognitive decliners for Alzheimer's Disease
Haiyang Zhang 1, Jason Goode 1, Michael Donahue 2, Ali Torkamani 3, Jared Cara 1, Julie Collens 1
1Vivid Genomics - San Diego (USA), 2University Of Southern California - Los Angeles (USA), 3Scripps Research Institute - San Diego (USA)

P51 Quick Dementia Rating System and its relationship to neuropsychological scores and biomarkers
Kevin Duff 1, Deborah Levine 2, Bruno Giordani 2, Angie Fagerlin 1, Nicole Fowler 3, John Hoffman 1
1University Of Utah - Salt Lake City, UT (USA), 2University Of Michigan - Ann Arbor, MI (USA), 3Indiana University - Bloomington, IN (USA)

P52 Can scores on the Repeatable Battery for the Assessment of Neuropsychological Status predict amyloid deposition?
Kevin Duff 1, Kayla Suhrie 1, Dustin Hammers 2, Ava Dixon 1, John Hoffman 1
1University Of Utah (USA), 2Indiana University (USA)

P53 Detection of Pre-clinical Alzheimer's Disease with Simultaneous Modeling of Underlying Cognitive Processes in Recall and Recognition Tests
Jason Bock 1, Michael Lee 2, William Shankle 1, 2, 3, Junko Hara 1, 3, Dennis Fortier 1, Tushar Mangrola 1
1Embic - Newport Beach (USA), 2Dept. Of Cognitive Sciences, University Of California At Irvine - Irvine (USA), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (USA)

P54 An exploration of minimal clinically important differences for cognitive outcomes in preclinical and prodromal stages – implications for clinical AD trials
Emma Borland 1, Chris Edgar 2, Erik Stomrud 1, Nicholas Cullen 1, Oskar Hansson 1, Sebastian Palmqvist 1
1Lund University - Lund (Sweden), 2Cogstate - London (United Kingdom)

P55 Evaluation relationships between subjective wellbeing, personality traits, and Alzheimer's disease: A two-sample Mendelian randomization study
Ya-Hui Ma 1, Yu-Xiang Yang 2, Qiang Dong 2, Lan Tan 3, Jin-Tai Yu 2
1Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China), 3Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Shanghai (China)

P56 Serum uric acid may aggravate Alzheimer's disease risk by affecting amyloidosis in cognitively intact older adults: The CABLE study
Lin-Lin Li 1, Ya-Hui Ma 2, Jin-Tai Yu 3
1Dalian Medical University - Dalian (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 3Fudan University - Shanghai (China)
The Amsterdam Instrumental Activities of Daily Living Questionnaire: Validation of a clinically meaningful outcome measure in asymptomatic and early symptomatic Alzheimer’s disease

Mark Dubbelman 1, Merel Postema 1, Philip Scheltens 1, Wiesje Van Der Flier 1, 2, Sietske Sikkes 1, 3
1Alzheimer Center Amsterdam, Department Of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), 2Department of Epidemiology and Biostatistics, Amsterdam UMC - Amsterdam (Netherlands), 3Department of Clinical, Neuro- & Developmental Psychology, Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

Monthly at-home computerized cognitive testing to detect diminished practice effects in preclinical Alzheimer’s disease

Roos J. Jutten 1, Dorene M. Rentz 1, 2, Rebecca E. Amariglio 1, 2, Rachel F. Buckley 1, 2, 3, Michael J. Properzi 1, Paul Maruff 4, 5, Craig E. Stark 6, Michael A. Yassa 6, Keith A. Johnson 1, Reisa A. Sperling 1, 2, Kathryn V. Papp 7, 2
1Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA), 2Department Of Neurology, Brigham and Women’s Hospital, Harvard Medical School - Boston (USA), 3Melbourne School of Psychological Sciences, University of Melbourne - Melbourne (Australia), 4The Florey Institute Of Neuroscience And Mental Health - Melbourne, Vic (Australia) - Melbourne (Australia), 5Cogstate Ltd. - Melbourne (Australia), 6University Of California, Irvine - Irvine (USA), 7Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (USA)

Use of app-based cognitive assessments during the COVID-19 pandemic: adherence and acceptability among cognitively normal older adults

Louisa Thompson 1, Karra Harrington 2, Nelson Roque 3, Jennifer Strenger 1, Stephen Correia 1, Richard Jones 1, Stephen Salloway 1, Martin Sliwinski 2
1Brown University Medical School - Providence (USA), 2Penn State University - University Park (USA), 3University Of Central Florida - Orlando (USA)

Metabolically healthy obesity and lipids may be protective factors for pathological changes of Alzheimer’s disease in cognitively normal adults

Shu-Juan Huang 1, Ya-Hui Ma 1, Lan Tan 1, Jin-Tai Yu 2
1Qingdao Municipal Hospital, Qingdao University - Qingdao (China), 2Fudan University - Shanghai (China)
P61 Estimates of Frontotemporal Dementia by geographic regions
Cai Gillis 1, Flavia Nery 1, Ellen Huang 1, Elena Ratti 1, Dana Flanders 2, Cathy Lally 3
1Biogen - Cambridge, Ma (USA), 2Emory University, Rollins School Of Public Health, - Atlanta, Ga (USA), 3Epidemiologic Research & Methods, Llc - Atlanta, Ga (USA)

P62 Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study
Ya-Hui Ma 1, Ya-Yu Wang 2, Lan Tan 3, Jin-Tai Yu 4
1Qingdao Municipal Hospital, College of Clinical Medicine, Qingdao University - Qingdao (China), 2Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Dalian (China), 3Qingdao Municipal Hospital, College of Clinical Medicine, Dalian Medical University - Qingdao (China), 4Fudan University - Shanghai (China)

P63 Distribution and baseline characteristics of participants with rapid progressing Alzheimer’s Disease as measured by CDR-SB over 78 weeks in the National Alzheimer’s Coordinating Center (NACC)
Cai Gillis 1, Nancy Maserejian 1, Ryan Miller 1
Biogen - Cambridge, MA (USA)

P64 PROSPECT-AD- Population-based scReening Over SPEech for Clinical Trials in AD
Alexandra König 1, Nicklas Linz 2, Craig Ritchie 3, Stefan Teipel 4, Bruno Dubois 5, Stephanie Bombois 5, Marc Teichmann 5, Sebastian Palmqvist 6, Oskar Hansson 6
1Institut National De Recherche En Informatique Et En Automatique (inria). Stars Team. Sophia Antipolis. Valbonne. France. - Valbonne (France), 2Ki:elements, Saarbrücken, Germany. - Saarbrücken (Germany), 3Edinburgh Dementia Prevention, University Of Edinburgh, Edinburgh, Uk. - Edinburgh (United Kingdom), 4German Center For Neurodegenerative Diseases (dzne), Rostock, Germany; Department Of Psychosomatic And Psychotherapeutic Medicine, University Of Rostock, Rostock, Germany. - Rostock (Germany), 5Hôpital Universitaire Pitié Salpêtrière, Institut De La Mémoire Et De La Maladie D’alzheimer – Im2a, Paris, France. - Paris (France), 6Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University, Lund, Sweden - Lund (Sweden)

P65 Optimizing paths for efficient use of digital health technologies in PD clinical trials: The Critical Path for Parkinson’s 3DT initiative
Derek Hill 1, Martijn Müller 2, Jesse Cedarbaum 3, Josh Cosman 4, Lauren Oliva 5, Mark Frasier 6, Marissa Dockendorf 7, Ariel Dowling 8, Kirsten Taylor 9, Emily Kunka 10, Caldeira Caldeira 11, Ray Dorsey 12, Diane Stephenson 2
1University College Of London - London (France), 2Critical Path Institute - Tucson (USA), 3Coerulesc Clinical Sciences - Woodbridge (USA), 4Abbvie - Cambridge (USA), 5Biogen - Cambridge (USA), 6The Michael J. Fox Foundation - New York (USA), 7Merck - Philadelphia (USA), 8Takeda - Social Circle (USA), 9Roche - Basel (Switzerland), 10Ucb - San Francisco (USA), 11Lundbeck - Copenhagen (Denmark), 12University Of Rochester - Rochester (USA)
P66 Reducing sources of variability of Digital Health Technologies in clinical trials by adding environmental context
Derek Hill 1, Tri Thanh Tam Tran 1, Nicolas Debrunoux 1, Alizee Devaux 1, Souleymen Sahoun 1
Panoramic Digital Health - Grenoble (France)

P67 Remote self-administration of cognitive tests in older adults with and without subjective cognitive decline using the BAC tablet-based ePRO platform
Alexandra Atkins 1, Mike Kraus 1, Matthew Welch 1, Joshua Yuan 1, Heather Stevens 1, Philip Harvey 2, Kathleen Welsh-Bohmer 3, 4, Richard Keefe 5, 4
1Verasci - Durham (USA), 2University Of Miami Miller School Of Medicine - Miami (USA), 3Verasci - Durham (USA minor outlying islands) - Durham (USA), 4Duke University Medical Center - Durham (USA), 5Verasci - Durham (USA) - Durham (USA minor outlying islands)

Theme: Health economics and clinical trials

P68 Staying sharp beyond the age of 65 years: A social marketing approach to the promotion of cognitive health in Luxembourg.
Mathilde Barbier 1, Anna Elena Kornadt 1, Carine Federspiel 2, Jean-Paul Steinmetz 2, Claus Vögele 1
1University Of Luxembourg - Esch-Sur-Alzette (Luxembourg), 2Zitha - Luxembourg (Luxembourg)

P69 Understanding Treatment Goals for Patients and Caregivers with Alzheimer’s Disease Along the Continuum of the Disease Consideration in Clinical Trial Design
David Gomez-Ulloa D 1, M Chris Runken 2, Wilton I Rodriguez 2, Basilio Hernandez 1, E Anne Davis 3, Paul Nisbet 4
1Grifols - Sant Cugat Del Vallès (Spain), 2Grifols Ssna - Research Triangle Park, Nc (USA), 3Xcenda - Palm Harbor (USA), 4One Research, Llc - Charleston, Sc (USA)

Theme: New therapies and clinical trials

P70 Phase I single (SAD) and Multiple Ascending Dose (MAD) studies evaluating the safety, tolerability Pharmacokinetics (PK) and Pharmacodynamics (PD) of YTX-7739, a novel brain penetrant small molecule SCD inhibitor, in healthy subjects
Ajay Verma 1, Brigitte Robertson 1
Yumanity Therapeutics - Boston (USA)

P71 Design of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 IN FTD-GRN
Sam Jackson 1, Michael Ward 1, Yijie Liao 1, Brian Mangal 1, Felix Yeh 1, Whedy Wang 1, Robert Paul 1
Alector - South San Francisco, Ca (USA)

P72 External Counterpulsation (Renew™ NCP-5 Device) for the Treatment of MCI due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type: A Pivotal Trial
Patrick Moriarty 1, Lauryn Gorby 1, David Salat 1, Jeffrey Burns 2, Tom Moreno 4, Jonathan Helfgott 4
1University Of Kansas Medical Center - Kansas City (USA), 2Harvard Medical School - Boston (USA), 3Kansas University Alzheimer’s Disease Center - Kansas City (USA), 4Renew Research - Farmington Hills (USA)
Theme: Proof of Concept/Translational research for Alzheimer Drug Development interventions

P73  Alzheimer’s disease prevention Within Reach by 2025: Targeted-Risk-AD-Prevention (TRAP) Strategy
Francesca Vitali 1, 2, 3, Gregory L. Branigan 1, 4, 5, Roberta D. Brinton 1, 6, 2
1Center For Innovation In Brain Science, University Of Arizona - Tucson (USA), 2Department of Neurology, University of Arizona - Tucson (USA), 3Center for Biomedical Informatics and Biostatistics, University of Arizona - Tucson (USA), 4Department of Pharmacology - Lawrence (USA), 5MD-PhD training program, College of Medicine, University of Arizona - Tucson (USA), 6Department of Pharmacology - Tucson (USA)

P74  An optimized Amyloid beta (Abeta) vaccine that safely drives immunity to the key pathological species of Alzheimer’s disease (AD)
Marija Vukicevic 1, Emma Fiorini 1, Rakel Carpintero 1, Marcela Rincon 1, Pilar Lopez-Deber 1, Nicolas Piot 1, Maxime Ayer 1, Inmaculada Rentero 1, Stefanie Siegert 1, Eva Gollwitzer 1, Sophie Bravo-Veyrat 1, Valérie Giriens 1, Catherine Morici 1, Marie-Gabrielle Beuzelin 1, Anthony Gesbert 1, Sébastien Rivot 1, Saskia Delpretti 1, Johannes Streffer 1, 2, Andrea Pfeifer 1, Marie Kosco-Vilbois 1
1Ac Immune Sa - Lausanne (Switzerland), 2University of Antwerp - Antwerp (Belgium)